Definitive Drug Testing Upcoding: The Bill Counts More Than the Lab Tested

Definitive drug testing upcoding means billing for a more extensive or more demanding drug test than the laboratory performed. A lab may claim a higher drug-class tier than its testing supports, or bill a complex method while using a simpler one. If you work at the bench, in billing or beside the ordering physician, you may see the mismatch before anyone outside the business does. The test order, the instrument’s work and the claim should tell the same story.

The class count also has to connect to the patient’s care. A laboratory can perform a broad panel and still face allegations that the physician never intended to order it. The question reaches back from the reimbursement code to the decision that put those tests on the requisition.

Presumptive and Definitive Testing Answer Different Questions

Presumptive testing screens for drugs or drug classes. Definitive testing identifies specific drugs and their metabolites. An immunoassay screen uses antibodies, while chromatography with mass spectrometry separates and identifies substances in the specimen. The difference matters when the bill represents work the method cannot do.

The clinical review Urine Drug Screening: A Guide to Monitoring Tx With Controlled Substances, published in The Journal of Family Practice in 2021, explains why a class label on a screen can be misleading. Many benzodiazepine immunoassays react poorly to clonazepam and lorazepam. A patient taking clonazepam can therefore test negative for benzodiazepines on that screen.

For an upcoding case, we connect what the method can detect to what the laboratory actually performed and represented on its claim.

Direct-to-definitive testing means the physician orders a definitive test without first ordering a presumptive screen. The HHS Office of Inspector General describes that route too. The original order then supplies the starting point for comparing the requested method and classes with the work performed and the service billed.

How G0480 Through G0483 and G0659 Work

G0480 through G0483 group definitive drug testing by the number of drug classes tested. The HHS Office of Inspector General’s June 2021 report, describing the 2019 Medicare fee schedule, sets out the bands:

• G0480: one to seven drug classes.
• G0481: eight to 14 drug classes.
• G0482: 15 to 21 drug classes.
• G0483: 22 or more drug classes.

The count concerns the classes tested. The number of positive results answers a different question: what the testing found. We compare the billed tier with the performed class menu, including testing that produced negative results.

G0659 sits outside that ascending class ladder. In the same report’s description of the codes used in 2019, it covered any number of classes tested using a simple definitive method. The report described G0480 through G0483 as using methods that identify individual drugs with recognized internal standards, calibration and quality-control materials.

A concern that a lab bills a G0659 method as G0483 definitive testing therefore calls for the method documentation as well as the class list. We examine what the procedure involved against the code requirements for the service date. An expansive menu and a high reimbursement code need a connection in the work performed.

When One Drug Class Becomes Thirteen

Counting each drug or metabolite as a separate class can inflate the tier even when the laboratory runs the same tests. The Inspector General’s review found that laboratories used different sources to decide how to count classes.

One laboratory counted benzodiazepines as one class. Another counted 13 drugs categorized as benzodiazepines as 13 separate classes. The government found that the Medicare contractors had not given laboratories clear, consistent class-counting guidance. The report described a system in which the same test could produce a different bill depending on how the classes were counted.

That is the practical issue behind an insider’s concern that a lab bills every drug metabolite as a separate drug class. The class-mapping document connects the individual substances in the method to the total entered for billing. The laboratory’s explanation of that mapping, and the guidance it used at the time, belong beside the result and the claim.

When that counting inflates a claim, taxpayers pay more for no additional laboratory work.

Why the Highest Tier Pays

The fee schedule gives laboratories a financial reason to pursue broader definitive testing. In the 2019 schedule reproduced by the Inspector General, the lowest definitive tier paid about $114 and the highest about $247. The payment changes with the category billed, making the class-selection decision valuable throughout a laboratory’s business.

The incentive has a history. On January 1, 2011, the Centers for Medicare & Medicaid Services increased the rate for the earlier screening code G0431 by 419% and changed its unit from each drug class to each encounter.

The four definitive tier rates stayed unchanged from 2018 through 2026, while the instrument-based presumptive rate fell before leveling off.

The business became substantial. A separate HHS Office of Inspector General audit of definitive drug testing reported approximately $3 billion in Medicare Part B payments for 17.1 million services from 2016 through 2020. Most services involved beneficiaries receiving pain-management treatment. That is the scale of the payment category in which a recurring top-tier claim operates.

A concentration of high-tier billing gives a review a place to start. What drove it matters: individual orders, broad default profiles, the counting method or instructions from inside the company. Those records connect the payment pattern to a decision.

The Order, the Method and the Claim Must Match

A G0483 drug class count unsupported by the instrument method puts the laboratory’s technical records at the center of the case. The method must support the work represented, and the specimen’s own testing record must show what was actually done.

The requisition identifies the requested testing. A custom profile may determine which tests follow from that request. The procedure manual and method validation describe the assay’s capabilities. The specimen’s output and released report show the result, while the claim shows what the laboratory asked the payer to buy.

For nonwaived testing, rules under the Clinical Laboratory Improvement Amendments require written procedures covering calibration, controls and the range the test can report. A laboratory must establish how a modified or lab-developed method performs before reporting patient results.

These are useful records for an insider who knows that the claimed service exceeds the method’s capability. If the concern is that a lab bills a definitive test without quantitative capability, we examine the reportable range, calibration records, actual output and the billed service’s requirements. That connects the concern to a particular method and claim.

CLIA’s test-report requirements identify the laboratory location where the work occurred, the test performed and the result. For a specimen sent elsewhere, that location helps connect the claim to the laboratory that did the work.

Medicare’s coverage framework, described in the Inspector General’s report, requires the treating clinician to order the test and use the results in care. Method validation addresses analytical performance. The patient’s order and clinical record explain why that testing belonged in the patient’s care.

Drug Testing Upcoding Cases Show Where the Records Diverge

Bluewater and the Inflated Class Count

Bluewater Toxicology agreed to pay $1,252,403 in July 2021 to resolve civil False Claims Act allegations involving urine drug testing. The Justice Department’s announcement described claims for the top definitive tier when the laboratory had tested fewer classes. The alleged conduct ran from January 2016 through September 2018 and involved Medicare and Medicaid, along with other federal health care programs. The case began with Bluewater’s disclosure of its own false claims.

The government also alleged that Bluewater submitted certain claims without sufficient documentation of the treating physician’s intent to order the billed test. That presents a second comparison within the same business: what the physician wanted against what the laboratory charged.

The class count and the order each supplied a route to the alleged overpayment. A biller could see the submitted tier. A technologist could see the performed menu. Someone working with the physician could know whether the broader test had ever been requested. Connecting those views is how we examine the claim.

Genotox Let Providers Preselect the Broad Panel

Genotox Laboratories admitted, in its civil settlement announced in April 2023, that it offered custom profiles allowing providers to preselect tests for all or nearly all patients. Those profiles generally selected the highest reimbursement categories, including the broadest definitive tier.

The whistleblower’s qui tam complaint alleged that even the name of the ordering arrangement was chosen to avoid attention:

The company’s admission about offering the profiles shows why the form matters: a provider could make one selection that applied across patients. The testing decision was built into the ordering arrangement before the next specimen arrived.

LabTox and the Method Behind the Bill

LabTox agreed to a $2,101,335 civil settlement in November 2019 over allegations that it billed high-complexity urine drug testing while using a low-complexity method. The Justice Department’s release also addressed separate specimen-validity billing.

A high-complexity urine code billed for a low-complexity method puts the performed procedure directly against the service described on the claim. The method used at the bench supplies the comparison. Bluewater’s class-count allegation and LabTox’s method allegation show different ways a claim can charge for more than the lab delivered.

When Are Toxicology Tests Unnecessary?

Toxicology tests are unnecessary when the testing lacks a patient-specific diagnostic or treatment purpose. The physician’s order, the reason for the selected classes and the use of the results connect the test to care. A broad profile applied across patients can replace that individual decision with the laboratory’s default.

Automatic reflex testing raises the same ordering question. Medicare’s ordering framework allows a treating clinician to request an additional test if the first result meets a specified condition. When a lab automatically runs a broad definitive panel alongside a presumptive screen, we examine whether the physician ordered that testing and whether the first result drove it, or whether the lab’s default replaced the clinical decision.

The Journal of Family Practice review recommends a risk-based approach and describes adjusting testing as the patient’s circumstances change. The service billed that day still needs its classes, its method and its patient-specific reason.

How Should Laboratory Tests Be Bundled for Medicare?

Definitive drug testing groups classes within a tier, and the claim must reflect the applicable code and service-date rules. In its review of 2019 claims, the Inspector General described medically unlikely edits that limited payment to one presumptive and one definitive drug-testing service per beneficiary per day.

That daily limit answers a units question. The order, class selection and method still need their own support. The review found that contractors lacked consistent class-counting guidance and adequate procedures to address repeated testing even with the daily edits in place. A paid claim can still lead to a review of those underlying records.

Can Specimen Validity Testing Be Billed Separately?

Medicare does not separately pay for specimen-validity testing performed as quality control with urine drug testing. The process checks whether a specimen has been diluted or adulterated.

The Bluewater announcement said Medicare guidance had stated that rule since January 2014. The government alleged that the laboratory nevertheless separately billed for specimen-validity testing. This adds another part of the same specimen’s billing history: quality-control work became an additional claim.

What the People Inside the Lab Can Show

The strongest account connects the original order, selected profile, performed method, class count, result and claim. The laboratory’s class-mapping records explain how individual substances became a tier. Instructions about test selection or code choice explain who made the decision that kept repeating.

A billing employee may know why a code became the default. A technical director may know the limits of the method. A practice employee may know whether the physician chose the tests or accepted a preset profile. We work with you to connect that knowledge to the laboratory’s claims and the payments they generated.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. Our role is to help you build the case around what happened inside the laboratory, from the testing decision to the bill.

When You Know What the Instrument Actually Did

If the billed tier exceeds the testing you know the lab performed, speak with our whistleblower experts about the method, the classes and the claims. We help you build your strongest laboratory fraud whistleblower case from that inside knowledge and bring in laboratory fraud whistleblower lawyers who understand toxicology and healthcare billing. We partner with you from the first call through the case.